Akebia Therapeutics Receives $41 Mln in Series C Financing
Akebia Therapeutics said on Tuesday that it has closed $41 million in Series C financing. The lead investor was Satter Investment Management, LLC, with Novo A/S as co-lead. Also participating in the round were existing investors Novartis Venture Funds, Kearny Venture Partners, Venture Investors LLC, Athenian Venture Partners, Triathlon Medical Ventures, AgeChem Venture and Sigvion Capital Fund. Seaview Securities LLC was the financial advisor to Akebia for the transaction. Based in Cincinnati, OH, Akebia Therapeutics is a biotech company focused on developing treatments for anemia and cancer.
4 June 2013•5 mins read
